RVMD — Revolution Medicines Share News
0.000.00%
Last trade - 00:00- $40.57bn
- $37.66bn
Revolution Medicines, Inc. reports results for the quarter ended June 30 - Earnings Summary
Revolution Medicines Inc expected to post a loss of $1.98 a share - Earnings Preview
Jefferies cuts Ipsen to 'underperform' on Somatuline competition risk
Brief: Revolution Medicines' New Drug Application For Daraxonrasib Accepted For Review By U.S. FDA
Cancer biotech Erasca rallies after upsized $550 mln share sale, analyst PT hikes
U.S. STOCKS ON THE MOVE-Vera Therapeutics, Vera Therapeutics, Nvidia
U.S. STOCKS ON THE MOVE-Revolution Medicines, Vivani Medical, Nvidia
U.S. STOCKS ON THE MOVE-Nvidia, Crinetics Pharmaceuticals, Rivian Automotive
EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill
Revolution Medicines rises as EU regulator starts phased review of cancer drug
Brief: EMA Fast Tracks Review Of Medicine For Metastatic Pancreatic Cancer
Media: Cancer drugmaker Revolution Medicines says sale not a priority - FT
Tango Therapeutics rises premarket after upsized $600 mln equity raise
IDEAYA Biosciences drops on $300 mln equity raise
IDEAYA Biosciences falls on $300 mln stock sale plans
Tango Therapeutics eases after launching $500 mln share offering
Tango Therapeutics jumps after pancreatic cancer drug combo shows promise in study
Tango Therapeutics' pancreatic cancer drug combo shows promise in study
'It's still working': More are living with cancer as era of targeted drugs takes hold